Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Melanoma

    Public invited to learn about VICC precision cancer medicine

    Friday, April 29th, 2016

    Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5:30 to 7:30 p.m. at the Vanderbilt Student Life Center, 310 25th Ave. S. The public is […]

    Melanoma response to immune therapy

    Friday, March 4th, 2016

    Anti-PD-1 therapy – a treatment that stimulates the immune system to attack tumors – produces responses in up to 40 percent of melanoma patients. Predictive markers of response are needed to optimize patient selection, improve treatment decision-making and minimize costs. Justin Balko, Pharm.D., Ph.D., Douglas Johnson, M.D., and colleagues hypothesized that tumor expression of MHC-I […]

    Combining treatments for melanoma

    Monday, February 22nd, 2016

    Chemotherapy and targeted anti-cancer drugs can induce tumor cell senescence. Although cell proliferation is shut down in senescent cells, there is enhanced expression of secreted factors that may promote or suppress tumor growth. Anna Vilgelm, Ph.D., and colleagues explored how therapy-induced senescence impacts the therapeutic response of melanoma. Using mouse models, the researchers assessed gene […]

    Investigators find clues to melanoma treatment resistance

    Friday, October 30th, 2015

    Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway. In recent years, new drugs have been approved that target the BRAF/MAPK […]

    New type of trial shows promise for several cancers

    Monday, August 24th, 2015

    Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation. The new clinical trial showed promising results in […]

    Veterans returning from Middle East face higher skin cancer risk

    Thursday, July 16th, 2015

    Soldiers who served in the glaring desert sunlight of Iraq and Afghanistan returned home with an increased risk of skin cancer, due not only to the desert climate, but also a lack of sun protection, Vanderbilt dermatologist Jennifer Powers, M.D., reports in a study published recently in the Journal of Investigative Dermatology. “The past decade […]

    Best hospital depends on cancer type

    Thursday, April 23rd, 2015

    The idea of a “Best Hospital for Cancer” does not reflect the fact that cancer comprises many different diseases. Jeffery Goldstein, M.D., Ph.D., a resident in the Department of Pathology, Microbiology and Immunology at Vanderbilt, and Vinay Prasad, M.D., MPH, aimed to rank the 50 highest ranked cancer hospitals – from the 2013 U.S. News […]

    NCI report shows U.S. cancer deaths on decline

    Thursday, April 2nd, 2015

    The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

    VICC’s Johnson to study cancer survivorship with immune inhibitor drugs

    Thursday, March 19th, 2015

    Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network  (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]

    BlackHawk’s support reaches milestone

    Thursday, February 12th, 2015

    Country music group BlackHawk recently presented a check for $20,000 to Harold (Hal) Moses, M.D., Ingram Professor of Cancer Research and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), in support of cancer research. Since 2006, the group has raised and donated $100,000 to VICC in remembrance of one of the original members of the multi-platinum […]

    Next Page »

    E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us